FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis ($1144.68, 0.00)
Transcript Intelligence: Almirall Q1 Earnings Guidance
Transcript Intelligence: Almirall Q1 Earnings Themes
Transcript Intelligence: Almirall Q1 Earnings Q&A
StreetAccount Summary - European pre-market trading update
Follow-up: Almirall Q1 performance aligned with expectations; Innovation pipeline tracking well; reaffirms 2026 guidance - slides (€11.96, 0.00)
Almirall reports Q1 net income €16.1M vs FactSet €16.7M [5 est, €13-19.2M] (€11.96, 0.00)
Evotec announces nomination of small molecule preclinical development candidate from its multi‑target drug discovery alliance in medical dermatology with Almirall S.A. (€5.24, 0.00)
Almirall expands collaboration with Barcelona Supercomputing Center (€13.00, 0.00)
StreetAccount Sector Summary - China Healthcare March Recap
Powered by FactSet Research Systems Inc.